BI Asset Management Fondsmaeglerselskab A S Has $7.63 Million Stock Position in Pfizer Inc. $PFE

BI Asset Management Fondsmaeglerselskab A S lowered its holdings in shares of Pfizer Inc. (NYSE:PFE) by 63.2% in the 3rd quarter, Holdings Channel.com reports. The fund owned 299,606 shares of the biopharmaceutical company’s stock after selling 514,481 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in Pfizer were worth $7,634,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Fiduciary Alliance LLC lifted its holdings in Pfizer by 46.4% during the third quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock valued at $3,701,000 after purchasing an additional 46,043 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in shares of Pfizer during the 3rd quarter valued at approximately $3,019,000. Vista Investment Partners LLC grew its stake in Pfizer by 236.1% in the 3rd quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock valued at $1,774,000 after buying an additional 48,900 shares in the last quarter. Money Concepts Capital Corp raised its holdings in Pfizer by 29.9% during the 3rd quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock valued at $6,325,000 after acquiring an additional 57,188 shares during the period. Finally, Generali Investments CEE investicni spolecnost a.s. lifted its position in shares of Pfizer by 76.4% during the third quarter. Generali Investments CEE investicni spolecnost a.s. now owns 109,269 shares of the biopharmaceutical company’s stock worth $2,784,000 after acquiring an additional 47,319 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently issued reports on PFE. Zacks Research lowered Pfizer from a “hold” rating to a “strong sell” rating in a research note on Monday, January 26th. HSBC reissued a “buy” rating and issued a $29.00 price target on shares of Pfizer in a report on Wednesday, December 10th. Morgan Stanley reduced their price objective on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research note on Friday, December 12th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Thursday, January 22nd. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Wednesday, December 17th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $28.06.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q4 beats — Pfizer reported 4Q revenue of $17.56B and adjusted EPS that beat consensus, reinforcing near‑term cash generation and supporting optimism about pipeline investments. Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most
• Positive Sentiment: GLP‑1 Phase 2b success — Lead obesity candidate MET‑097i (VESPER‑3) met its primary endpoint with up to 12.3% placebo‑adjusted weight loss and sustained effect after switching dosing cadence, giving Pfizer a credible entry into a fast‑growing GLP‑1 market. This is a near‑term clinical catalyst that drove recent upside. Pfizer Announces Positive Phase 2b Results for Obesity Drug
• Positive Sentiment: Oncology + AI growth story — Analysts and analysts’ commentary highlight Pfizer’s expanded oncology pipeline (post‑Seagen) and broad AI partnerships that management says will speed discovery and cut costs, offering multiple medium‑to‑long‑term revenue drivers beyond GLP‑1. Growth from Oncology and AI
• Neutral Sentiment: TrumpRx discounts — Pfizer launched a program on TrumpRx offering discounts on 30+ medicines to improve affordability; positive for access/reputation but could pressure list prices or commercial mix (impact on earnings unclear). Pfizer Launches Cost Savings Program on TrumpRx
• Neutral Sentiment: FY‑2026 guidance mixed — Pfizer gave EPS guidance of $2.80–3.00 (midpoint slightly below some consensus) and revenue guidance that straddles estimates; this tempering likely capped the rally as investors parsed sustainability. Guidance Update
• Negative Sentiment: Market reaction and analyst caution — Despite the beats and clinical news, some outlets reported a mixed investor response to the weight‑loss data and a few firms maintained Hold/neutral ratings or modest price targets, which contributed to the pullback in PFE today. Analysts See Cautious Upside
• Negative Sentiment: Program pauses — Updates that paused some modRNA shingles work with BioNTech introduce specific R&D uncertainty and are a reminder of binary clinical risks across the pipeline. Pfizer and BioNTech Pause modRNA Shingles Ambitions

Pfizer Price Performance

Shares of NYSE:PFE opened at $26.49 on Friday. The company’s fifty day moving average price is $25.58 and its 200-day moving average price is $25.08. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The firm has a market capitalization of $150.60 billion, a price-to-earnings ratio of 19.48 and a beta of 0.47. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.69.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.09. The company had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The firm’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.63 earnings per share. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.5%. Pfizer’s dividend payout ratio is 126.47%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.